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Abstract 
Background: Angiotensin converting enzyme inhibitors (ACEIs) are recommended as first-
line therapy in patients with heart failure with reduced ejection fraction (HFrEF). The 
comparative effectiveness of different ACEIs is not known. 
Methods and results: 4,723 out-patients with stable HFrEF prescribed either enalapril, 
lisinopril, or ramipril were identified from three registries in Norway, England, and Germany. 
In three separate matching procedures, patients were individually matched with respect to 
both dose equivalents and their respective propensity scores for ACEI treatment.  
During a follow-up of 21,939 patient-years, 360 (49.5%), 337 (52.4%), and 1,119 (33.4%) 
patients died amongst those prescribed enalapril, lisinopril, and ramipril, respectively. In 
univariable analysis of the general sample, enalapril and lisinopril were both associated with 
higher mortality as compared with ramipril treatment (HR 1.46, 95% CI 1.30-1.65, p<0.001, 
and HR 1.38, CI 1.22-1.56, p<0.001, respectively). Patients prescribed enalapril or lisinopril 
had similar mortality (HR 1.06, 95% CI 0.92-1.24, p=0.41). However, there was no significant 
association between ACEI choice and all-cause mortality in any of the matched samples (HR 
1.07, 95% CI 0.91-1.25, p=0.40; HR 1.12, 95% CI 0.96-1.32, p=0.16; and HR 1.08, HR 1.10, 
95% CI 0.93-1.31, p=0.25 for enalapril vs. ramipril, lisinopril vs. ramipril, and enalapril vs. 
lisinopril, respectively). Results were confirmed in subgroup analyses with respect to age, 
sex, left ventricular ejection fraction, NYHA functional class, cause of HFrEF, rhythm, and 
systolic blood pressure. 
Conclusion: Our results suggest that enalapril, lisinopril and ramipril are equally effective in 
the treatment of patients with HFrEF when given at equivalent doses. Words: 249 
Key words: heart failure with reduced ejection fraction, angiotensin converting enzyme 
inhibitors, effectiveness, mortality 
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Introduction 
Angiotensin converting-enzyme inhibitors (ACEIs) are recommended as first-line treatment 
for patients with heart failure with reduced ejection fraction (HFrEF), since randomized 
clinical trials have shown a reduction in all-cause mortality of 20–30% with ACEIs as 
compared with placebo (1-3). . However, only enalapril and lisinopril were tested in patients 
with chronic HFrEF (4-7). In contrast, other ACEIs were investigated in patients after 
myocardial infarction with differing degrees of left ventricular systolic dysfunction (8-10). 
Moreover, individual ACEIs differ in terms of their half-lives, bioavailability, lipophilicity, tissue 
penetration, bradykinin site selectivity, and routes of elimination (11). These distinct 
pharmacokinetic characteristics may result in varying effectiveness. To date, there are no 
large-scale trials comparing the effect of different ACEIs on survival in patients with HFrEF, 
and small head-to-head comparisons did not include the commonly used ACEIs enalapril, 
lisinopril, and ramipril (12-16). An early meta-analysis of randomized ACEI trials suggested a 
class effect of ACEIs (3), whereas a recently published network meta-analysis reported 
better survival with ramipril as compared with lisinopril or enalapril (17). However, patient 
characteristics varied significantly between trials and indirect between-trial comparisons may 
therefore not be reliable. In addition, the network meta-analysis included only 111 ramipril 
users with a short-term follow-up of 3 months, and it did not account for ACEI dosing. Thus, 
results should be interpreted with caution. Since head-to-head trials of ACEIs in patients with 
congestive heart failure are unlikely to be conducted, high-quality observational studies may 
be valuable to inform clinical decisions. We therefore compared the prognosis of patients 
prescribed enalapril, lisinopril or ramipril in a contemporary multicentre real-world cohort of 
patients with stable HFrEF from three European countries. 
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Methods 
Databases 
Patients’ data were extracted from three different European heart failure databases: the 
Norwegian Heart Failure Registry, the Heart Failure Registry of the Department of Academic 
Cardiology, University of Hull, UK, and the Heart Failure Registry of the University of 
Heidelberg, Germany. Recruitment was prospective and continuous for each database and 
centre. All patients gave their written informed consent for data storage and evaluation. The 
study conformed to the principles outlined in the Declaration of Helsinki and was approved by 
the local ethics committees.  
The Norwegian Heart Failure Registry was initiated in October 2000 and patients were 
enrolled from the outpatient clinics of 27 recruiting hospitals well distributed in all regions of 
Norway ranging in size and scope from small community to large university hospitals. The 
participating centres recorded their data using a web-based database. 
Patients who attended the community heart failure clinics of the University of Hull, UK, and 
the University of Heidelberg, Germany, for evaluation of heart failure were offered inclusion 
into the local heart failure registries. Since both university hospitals are providers of 
secondary and tertiary care, the registries reflect a broad representation of patients of their 
respective regions. 
Patient selection and follow-up 
All databases reflect all-comer cohorts. Patients were included after stabilization of both 
clinical status and medication. Patients were eligible for the study if they met all of the 
following criteria: a) attendance at the heart failure outpatient clinic of any of the participating 
hospitals, b) written informed consent for inclusion into the respective heart failure registry, c) 
diagnosis of HFrEF, and d) treatment with captopril, enalapril, lisinopril, ramipril, or 
trandolapril. In the complete database, however, captopril and trandolapril were hardly used 
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in any of the three participating registries. We therefore restricted to our analysis to enalapril, 
lisinopril and ramipril. 
Medication was at the discretion of the referring physician. Target doses and dose 
equivalents for ACEIs were derived from ESC guidelines for the diagnosis and treatment of 
acute and chronic heart failure (1). For example, daily doses of 10 mg ramipril, 20 mg 
enalapril or 20 mg lisinopril were considered as 100% dose equivalent, while 5 mg ramipril, 
10 mg enalapril or 10 mg lisinopril were defined as 50% dose equivalent. 
 
The diagnosis of heart failure was established according to guidelines on the basis of typical 
symptoms and signs associated with an objective abnormality of cardiac structure or function 
on echocardiography, cardiac magnetic resonance imaging, or left heart catheterisation (1). 
All included patients had a left ventricular ejection fraction (LVEF) <45%.  
Baseline characteristics included medical history, physical examination, LVEF, blood count 
and chemistry, and medication. Glomerular filtration rate (GFR) was estimated using the 
modification of diet in renal disease (MDRD) formula (18).  
Surviving patients were followed up for a minimum of six months. Determination of survival 
status and follow-up were performed by scheduled visits to the outpatient clinic, by telephone 
calls either to the patients’ homes or to their physicians, or by electronic hospital records. For 
the purpose of the present analysis, patients were censored as “alive” at the date of this last 
contact. In addition, for the Norwegian Heart Failure Registry, mortality data were obtained at 
regular intervals from the National Statistics Bureau and no patient was lost to follow-up. All-
cause mortality was the predefined endpoint of the study.  
Statistical analysis 
All tests are two-tailed and a P-value of less than 5% was regarded as being statistically 
significant. Variables are presented as mean ± standard deviation, median [interquartile 
range], or number [percentages (%)] as appropriate. Chi-squared tests were used to 
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compare frequencies. To test for significant differences between groups, the Kruskal-Wallis 
test and analysis of variance (ANOVA) tests were used where appropriate. 
In order to prevent bias in further statistical analyses due to missing baseline values, we 
performed a multiple imputation analysis with n=100 repetitions using the Markov chain 
Monte Carlo method (MCMC). This procedure replaces each missing value with a set of 
plausible values that represent the uncertainty about the correct value for imputation. 
Differences in event-free survival between patients treated with enalapril, lisinopril, or ramipril 
were analysed using Cox proportional hazard models and displayed using the Kaplan-Meier 
method for survival. To account for possible confounders, patients were matched with 
respect to ACEI treatment using pairwise multi-level propensity score matching as described 
below. Survival analyses were then repeated in matched cohorts.  
Propensity score calculation and matching 
Propensity scores were calculated as the single composite variable from a non-parsimonious 
multivariate logit-linked binary logistic regression of the baseline characteristics. The ACEI 
agent was the dependent variable (19). In a first step, propensity scores were calculated 
separately for “enalapril vs. ramipril”, “lisinopril vs. ramipril”, and “enalapril vs. lisinopril” as 
dependent variables. Propensity scores were derived from all baseline variables except for 
ACEI dose equivalent, haemoglobin, and NT-proBNP using the multiple imputed baseline 
data sets. Dose equivalent of the respective ACEI was not part of the propensity scores as it 
was used as a separate matching criterion. Haemoglobin and NT-proBNP were excluded 
due to a large number of missing variables. The logits of the probability of receiving a certain 
ACEI according to the respective propensity scores formed the basis of three separate 
matching procedures.  
Patients were individually matched for both the propensity of receiving a particular ACEI and 
their dose equivalents. Each matching procedure was performed in two steps: First, calliper 
matching of the propensity score was applied with calliper size predefined as 0.2 of the 
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standard deviation of the total sample. In a one-pass procedure starting with a given patient 
receiving a certain ACEI (e.g. enalapril), the closest match of a patient receiving a different 
ACEI (e.g. ramipril) was identified. Second, dose equivalents for the ACEIs were compared. 
If doses were equivalent or varied ≤10%, the pair of patients was retained for analysis and 
removed from the total sample to allow for the next matching cycle to take place. If doses 
varied >10%, the pair was rejected. Then the first step of the matching process was repeated 
to identify the next closest match to the given enalapril patient of the failed match according 
to the propensity score. If a further patient on ramipril was thus identified, the second step 
was repeated. If no match according to the propensity score AND dose equivalent could be 
identified, the enalapril patient was removed from the total sample and the matching cycle 
started with the next ramipril patient. 
The matching procedures of patients treated with enalapril vs. lisinopril and lisinopril vs. 
ramipril were performed analogously. Owing to this statistical design, the matched patients 
included in each drug cohort differed between comparisons.  
Bias reduction, balance and sensitivity analysis 
The balance of baseline covariates before and after matching was assessed using 
standardised differences (20). In addition, Chi-squared test, Mann-Whitney-U test, and 
student’s t-test were used to test for differences in baseline variables after matching. As a 
sensitivity analysis to univariable survival analyses in the matched samples, we performed 
multivariable Cox regression analyses including significant covariates in the matched 
samples. Furthermore, we performed a multivariable Cox regression analysis in the general 
sample including covariates that were significant in univariable analyses. Finally, we 
conducted a formal sensitivity analysis to quantify the degree of a hidden bias that would 
need to be present to invalidate our main conclusions following the method suggested by 
Love (21).  
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Subgroups 
Analyses were repeated in pre-specified subgroups of the matched samples with respect to 
age (above vs. below median), sex, LVEF (≤35% vs. >35%), NYHA functional class (I/II vs. 
III/IV), rhythm (sinus rhythm yes vs. no), cause of heart failure (ischaemic vs. non-ischaemic), 
and systolic blood pressure (≤120mmHg vs. >120mmHg). Interaction terms were calculated 
for each of the predefined subgroups in the propensity matched samples. 
 
Results 
We identified 8,005 patients with HFrEF in the three heart failure databases. Figure 1 shows 
the composition and selection flow with respect to the different ACEIs in our study 
population. Of 4,723 patients who met the inclusion criteria outlined above, 3,074 patients 
were from Norway, 837 patients were from Germany, and 812 patients were from England.  
Enalapril was prescribed for 727 patients (15.4%) with a median dose of 20 (10-20)mg/d 
(equivalent to 100 (50-100)% of target dose), lisinopril for 643 patients (13.6%) with a median 
dose of 20 (10-20)mg/d (equivalent to 100 (50-100)% of target dose), and ramipril for 3,353 
patients with a median dose of 10 (5-10)mg/d (equivalent to 100 (50-100)% of target dose).  
Baseline characteristics of HFrEF patients differed with respect to ACEI treatment for a 
number of variables (table 1). Overall, patients receiving ramipril were younger and more 
likely to have NYHA functional class I or II symptoms than those on enalapril and lisinopril. 
NT-proBNP levels were lower in the ramipril group, whereas LVEF was similar in all three 
treatment groups. In patients using lisinopril, systolic blood pressure was significantly higher 
as compared to patients on enalapril or ramipril. 
Total follow-up was 263,265 patient-months (21,939 patient-years) with a median follow-up 
duration of 50 (27-80) months. For enalapril, median follow-up was 50 (24-80) months, 
whereas it was 55 (28-90) months and 49 (27-77) months for lisinopril and ramipril, 
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respectively. During that time 1,816 (38.5%) patients died: 360 (49.5%) on enalapril, 337 
(52.4%) on lisinopril, and 1,119 (33.4%) on ramipril. 
In univariable analysis of the overall cohort, patients prescribed enalapril and lisinopril both 
had higher mortality when compared with those prescribed ramipril (HR 1.46, 95% CI 1.30-
1.65, p<0.001, and HR 1.38, CI 1.22-1.56, p<0.001, respectively). Survival on enalapril was 
similar to that on lisinopril (HR 1.06, 95% CI 0.92-1.24, p=0.41). Kaplan–Meier curves for 10-
year survival with respect to ACEI treatment are shown in figure 2. 
The matching procedures identified 688, 622 and 538 pairs of patients with similar dose-
equivalent for each of the three comparisons (enalapril vs. ramipril, lisinopril vs. ramipril and 
enalapril vs. lisinopril). Of these, 639 (46%), 589 (47%), and 551 (51%) patients died during 
follow-up, respectively. Each of the propensity score matching procedures significantly 
reduced standardized differences below 10% in the absolute values for most observed 
covariates, demonstrating a substantial improvement in the covariate balance across the 
treatment groups (figure 3 a) and b)). However, matched patients treated with enalapril or 
ramipril differed with respect to NT-proBNP levels (1,065 (482-2,170) ng/l vs.1,311 (604-
2,881) ng/l, p=0.03) and loop diuretic dose (40 (40-80) mg vs. 40 (20-80) mg, p=0.007), while 
matched patients using enalapril or lisinopril varied with respect to haemoglobin 
concentrations (13.5±1.6 g/dl vs. 13.8±1.4 g/dl, p=0.02). Detailed descriptions of the matched 
samples are available in the supplementary material online (Tables 2-4). 
Univariable Cox proportional hazard analyses did not find any significant association 
between the particular ACEIs prescribed and all-cause mortality in any of the matched 
samples (enalapril vs. ramipril, HR 1.07, 95% CI 0.91-1.25, p=0.40; lisinopril vs. ramipril, HR 
1.12, 95% CI 0.96-1.32, p=0.16; enalapril vs. lisinopril, HR 1.10, 95% CI 0.93-1.31, p=0.25). 
Results were confirmed after adjusting for covariates in the matched samples (HR 1.03, 95% 
CI 0.78-1.37, p=0.84 for enalapril versus ramipril, and HR 0.97, 95% CI 0.74-1.26, P=0.81 for 
enalapril versus lisinopril, respectively). The Kaplan–Meier curves for survival of matched 
HFrEF patients with respect to ACEI treatment are presented in figures 4-6.  
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Similarly, we found no relationship between the type of ACEI and all-cause mortality in 
multivariable Cox regression analysis of the general sample including significant variables 
from univariable analyses (HR 1.19, 95% CI 0.79-1.79, p=0.41 for enalapril versus lisinopril, 
HR 1.31, 95% CI 0.97-1.77, p=0.08 for enalapril versus ramipril, and HR 1.13, 95% CI 0.81-
1.57, P=0.48 for lisinopril versus ramipril, respectively),  
Subgroup analyses confirmed that none of the ACEIs was superior to one of the others. The 
relevant plot is shown in figure 7.  
The formal sensitivity analyses indicate only a small residual bias. The respective Γ-values 
were 0.73, 0.64, and 0.80 for enalapril vs. ramipril, lisinopril vs. ramipril, and enalapril vs. 
lisinopril (no residual bias at Γ=1.0). This means that in order to attribute a possible survival 
benefit to an unobserved covariate rather than the receipt of e.g. enalapril (vs. lisinopril), that 
unobserved covariate would only need to produce a 20% increase in the odds of receipt of 
enalapril while being a weak predictor of all-cause mortality.  
 
Discussion 
In this European multicentre cohort study of outpatients with stable HFrEF, we analysed the 
association of treatment with the 3 ACEIs enalapril, lisinopril and ramipril and survival. Our 
main findings are that 
 patient characteristics differed significantly between treatment groups. Ramipril users 
were younger, had lower NT-proBNP levels and were in a lower NYHA functional 
class that enalapril and lisinopril users. 
 consequently, treatment with ramipril was superior to enalapril and lisinopril therapy in 
univariable analysis of the general sample. 
 after controlling for confounders and ACEI dose, no difference in survival was noted 
between the 3 individual ACEIs. 
 results were consistent through a range of important subgroups. 
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Although substantial evidence exists to support the use of ACEIs in patients with HFrEF, 
there is little evidence and conflicting literature on the relative effectiveness of different 
ACEIs in everyday use (22-27).  
Our study contrasts to other observational studies suggesting a different effectiveness of 
individual ACEIs in heart failure patients (24-27). Two large retrospective analyses from 
Canadian administrative databases including elderly patients admitted for heart failure (24) 
and after myocardial infarction (25) reported better outcomes with ramipril as compared with 
enalapril. In addition, in data from almost 140,000 patients with heart failure from the 
American Veterans Health Administration (26, 27), lisinopril was associated with lower 
mortality than captopril, whereas enalapril was equally effective as captopril (26). 
Unfortunately, no comparison was performed between lisinopril and enalapril, and ramipril 
was not included in the analysis. An important limitation of both the Canadian and the 
American studies, however, is the lack of information on relevant patient characteristics such 
as LVEF, type of heart failure, and NYHA functional class. The results may accordingly be 
susceptible to confounding by indication and severity of heart failure. Likewise, we found 
better survival in ramipril users in univariable analyses of the general sample. After 
controlling for important covariates including LVEF, NYHA functional class and NT-proBNP, 
however, outcomes were similar between treatments. Then again, another Canadian study of 
6,753 patients with newly diagnosed heart failure found no significant differences between 
enalapril, lisinopril, and ramipril in terms of heart failure effectiveness (23). Similarly, a recent 
analysis of 7,291 patients with HFrEF from the Danish Heart Failure Registry suggested an 
equal reduction in all-cause mortality with the use of enalapril as compared with ramipril (22).  
Our study supports the results from the Danish study while paying particular attention on 
equivalent dosing of ACEIs. The Assessment of Treatment with Lisinopril and Survival 
(ATLAS) trial reported significantly better outcomes in patients treated with high doses of 
lisinopril as compared with low-dose users (7). Therefore, inclusion of ACEI dosing in the 
comparison of different ACEIs in patients with HFrEF seems crucial.  
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In agreement with the Danish cohort study (22), we confirmed equal effectiveness of ACEIs 
in subgroup analyses with respect to age, sex, LVEF, NYHA functional class, and cause of 
heart failure. In addition, outcomes were verified in subgroups of patients according to heart 
rhythm and systolic blood pressure. As there are no other studies on the relative 
effectiveness of ACEIs providing subgroup analyses, our study expands the available 
evidence. 
 
Limitations 
As with any non-randomized, observational design, the present study may be subject to 
unmeasured confounders. Sensitivity analyses cannot prove or rule out the presence of such 
an unmeasured confounder. However, our data result from comprehensive outpatient 
databases with continuous, prospective inclusion and close surveillance. The detailed 
characterization of patients allows consideration of various potential confounders through the 
use of comprehensive propensity score and multivariable Cox regression models. The large 
sample size and prospective inclusion of patients from three European countries are obvious 
strengths of the present study. The results are therefore likely to be generalizable to other 
HFrEF populations. We observed substantial differences in patient characteristics between 
countries, with the majority of patients being recruited in Norway. However, as patient 
characteristics were used for propensity score calculation and matching, we expect that this 
should not have an impact on our results in the matched cohorts. In addition, country did not 
have a significant, independent impact on survival when entered as a covariate in 
multivariable Cox regression analysis (p=0.86). We further cannot comment on the specific 
reasons for selection of a particular ACEI, nor on medication adherence. In addition, our data 
do not allow identification of patients who either switched from one ACEI to another or 
changed ACEI dosing during follow-up. As inclusion into the analyses of our study was 
performed after stabilization of both clinical status and medication in an ambulatory setting, 
however, this may reduce the necessity for further modulation of ACEI treatment. 
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From this observational study, we can infer that there is no association between the ACEI 
prescribed and mortality but we cannot be sure that the lack of observed difference truly 
reflects similar benefit. Ideally, our results should be confirmed in a large-scale, randomized 
head-to-head comparison of ACEIs. Given the required sample size and associated costs, 
such a trial may never be done. 
 
Conclusion 
In this European multicentre cohort study of patients with HFrEF, we found no difference in 
all-cause mortality for patients treated with enalapril, lisinopril or ramipril. The results were 
consistent in subgroups with respect to age, sex, NYHA functional class, LVEF, sinus 
rhythm, cause of heart failure, and blood pressure. These findings support the assumption of 
a class effect among the 3 ACEIs on mortality in patients with HFrEF. 
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Figure legends 
Figure 1:  
Title: Inclusion of ACEI users in study cohort. 
Legend: ACEI, angiotensin converting enzyme inhibitor 
 
Figure 2:  
Title: Kaplan–Meier curves for 10-year survival for hospital outpatients with chronic heart 
failure with reduced ejection fraction receiving enalapril, lisinopril, and ramipril, respectively. 
 
Figure 3 a) and b):  
Title: Absolute standardized differences before (a) and after (b) propensity score matching 
comparing covariate values for hospital outpatients with chronic heart failure with reduced 
ejection fraction receiving enalapril vs. ramipril, lisonopril vs. ramipril, and enalapril vs. 
lisinopril, respectively. 
Legend: BMI, body mass index; NYHA, New York Heart Association functional class; OPD, 
obstructive pulmonary disease; aHT, arterial hypertension; BPsys, systolic blood pressure; 
HR, heart rate; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration 
rate using the Modification of Diet in Renal Disease equation; ACEI, angiotensin converting 
enzyme.  
 
Figure 4:  
Title: Kaplan–Meier curves for 10-year survival regarding all-cause mortality in the 
propensity and dose-equivalent matched cohort for hospital outpatients with chronic heart 
failure with reduced ejection fraction receiving enalapril or ramipril. 
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Figure 5:  
Title: Kaplan–Meier curves for 10-year survival regarding all-cause mortality in the 
propensity and dose-equivalent matched cohort for hospital outpatients with chronic heart 
failure with reduced ejection fraction receiving lisinopril or ramipril. 
 
Figure 6:  
Title: Kaplan–Meier curves for 10-year survival regarding all-cause mortality in the 
propensity and dose-equivalent matched cohort for hospital outpatients with chronic heart 
failure with reduced ejection fraction receiving enalapril or lisinopril. 
 
Figure 7:  
Title: Cox regression analyses for all-cause mortality regarding ACEI use in the predefined 
subgroups for the propensity score matched cohorts 
Legend: RRsys, systolic blood pressure; HFrEF, heart failure with reduced ejection fraction; 
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional class. 
*P for interaction refers to subgroups of each propensity matched sample. 
 
 
 
Table 1: Baseline characteristics of CHF patients with respect to ACEI treatment 
 All patients 
n=4,723 
Enalapril 
n=727 
Lisinopril 
n=643 
Ramipril 
n=3,353 
P-
value 
P-
value* 
Age, y [n=4,723] 67±13 68±12 70±12 66±13 <0.001 <0.001 
Men, n(%) [n=4,723] 3,609 (76.4) 553 (76.1) 480 (74.7) 2,576 (76.8) 0.48 0.02 
BMI, kg/m² [n=4,375] 27.0±5.1 27.2±5.2 26.9±5.0 27.0±5.1 0.49 <0.001 
Heart Failure Registry  
[n=4,723] 
     n.a. 
Norway, n(%) 3,074 (65.1) 515 (70.8) 456 (70.9) 2,105 (62.8)   
Heidelberg, n(%) 837 (17.7) 114 (15.7) 50 (7.8) 673 (20.1)   
Hull, n(%) 812 (17.2) 98 (13.5) 139 (21.6) 575 (17.1)   
Cause of HFrEF 
[n=4,723] 
    0.49 <0.001 
Ischaemic, n(%) 2,810 (59.5) 447 (61.5) 379 (58.9) 1,984 (59.2)   
Non-ischaemic, n(%) 1,913 (40.5) 280 (38.5) 264 (41.1) 1,369 (40.8)   
NYHA, n(%) [n=4,656]     <0.001 <0.001 
I 823 (17.7) 76 (10.6) 77 (12.2) 670 (20.2)   
II 2,469 (53.0) 393 (54.7) 329 (52.2) 1,747 (52.7)   
III 1,332 (28.6) 245 (34.1) 214 (34.0) 873 (26.4)   
IV 37 (0.8) 4 (0.6) 10 (1.6) 23 (0.7)   
LVEF, % [n=4,147] 30±9 29±9 30±9 30±8 0.09 <0.001 
BPsys, mmHg [n=4,674]  123±21 123±21 126±23 122±21 0.002 <0.001 
Sinus rhythm, n(%) 
[n=4,723] 
2,633 (55.7) 384 (52.8) 339 (52.7) 1,910 (57.0) 0.03 <0.001 
HR, 1/min [n=4,670] 69±13 68±13 70±14 68±13 0.12 <0.001 
NT-proBNP, pg/mL 
[n=2,103] 
1,012 
(369-2,399) 
1,069 
(483-2,248) 
1,166 
(497-2,636) 
949 
(338-2,392) 
0.01 <0.001 
Table 1
Creatinine, µmol/L 
[n=4,590] 
96 (81-118) 
102 (83-
126) 
102 (85-
128) 
94 (80-115) <0.001 <0.001 
eGFR, mL/min/1.73m² 
[n=4,590] 
65 (50-83) 61 (46-80) 60 (46-76) 67 (52-85) <0.001 <0.001 
Sodium, mmol/L 
[n=5,572] 
140 ± 3 139 ± 3 140 ± 3 140 ± 3 0.056 <0.001 
Potassium, mmol/L 
[n=4,572] 
4.4±0.4 4.5±0.5 4.4±0.4 4.4±0.4 0.001 <0.001 
Haemoglobin, g/dL 
[n=2,654] 
13.8 ± 1.5 13.6 ± 1.6 13.8 ± 1.5 13.8 ± 1.5 0.01 0.29 
Comorbidities, n(%)       
OPD [n=4,723] 590 (12.5) 88 (12.1) 72 (11.2) 430 (12.8) 0.49 <0.001 
aHT [n=4,723] 1,739 (36.8) 282 (38.8) 226 (35.1) 1,231 (3.7) 0.37 <0.001 
Hyperlipidaemia 
[n=4,723] 
2,265 (48.0) 359 (49.4) 280 (43.5) 1,626 (48.5) 0.06 <0.001 
Smoker [n=4,723] 763 (16.1) 113 (15.5) 104 (16.2) 546 (16.3) <0.001 <0.001 
Stroke [n=4,723] 317 (6.7) 65 (8.9) 47 (7.3) 205 (6.1) 0.007 <0.001 
PVD [n=4,723] 294 (6.2) 47 (6.5) 29 (4.5) 218 (6.5) 0.03 <0.001 
Diabetes [n=4,723] 918 (19.1) 162 (22.3) 115 (17.9) 641 (19.4) 0.08 <0.001 
Treatment       
ACEI dose 
equivalent, % 
[n=4,723] 
100  
(50-100)  
[79±32] 
100  
(50-100)  
[81±37] 
100  
(50-100)  
[73±37] 
100  
(50-100)  
[80±30] 
<0.001 <0.001 
Beta-blocker, n(%) 
[n=4,723] 
4,143 (87.7) 610 (83.9) 528 (82.1) 3,005 (89.6) <0.001 <0.001 
Beta-blocker dose 
equivalent, % 
53 (26-100) 
[63±36] 
53 (26-100) 
[62±35] 
53 (26-100) 
[68±36] 
53 (26-100) 
[63±36] 
0.80 <0.001 
[n=4,143] 
ARB, n(%) [n=4,723] 176 (3.7) 26 (3.6) 15 (2.3) 135 (4.0) 0.11 <0.001 
MRA, n(%) [n=4,717] 1,506 (31.9) 226 (31.2) 167 (26.0) 1,113 (33.2) 0.001 <0.001 
Loop diuretic, n(%) 
[n=4,723] 
3,524 (74.6) 595 (81.8) 517 (80.4) 2,412 (71.9) <0.001 <0.001 
Loop diuretic dose, 
mg furosemide 
[n=3,524] 
40 (20-80) 40 (40-80) 40 (40-80) 40 (20-80) <0.001 <0.001 
Aspirin, n(%) 
[n=4,723] 
1,905 (40.3) 257 (35.4) 224 (34.8) 1,424 (42.5) <0.001 <0.001 
Statin, n(%) 
[n=4,723] 
2,548 (53.9) 385 (53.0) 336 (52.3) 1,827 (54.5) 0.49 <0.001 
Values shown are mean±SD or median (interquartile range). P-values <0.05 are written in italics. P-value* refers to 
comparisons of unadjusted variables between countries. n, number; ACEI, angiotensin converting enzyme inhibitor; BMI, 
body mass index; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association; LVEF, left 
ventricular ejection fraction; BPsys, systolic blood pressure; HR, heart rate; eGFR, estimated glomerular filtration rate 
calculated using the Modification of Diet in Renal Disease equation; OPD, obstructive pulmonary disease; aHT, arterial 
hypertension; PVD, peripheral vascular disease; ARB, angiotensin receptor antagonist; MRA, mineralocorticoid receptor 
antagonist. Dose equivalent represent percentage achieved of the individual drug with respect to the guideline recommended 
target dose.  
 
Table 2: Baseline characteristics of matched CHF patients treated with enalapril or ramipril 
 Enalapril 
n=688 
Ramipril 
n=688 
P-value 
Age, y  68±13 68±13 0.74 
Men, n(%)  525 (76.3) 514 (74.7) 0.49 
BMI, kg/m²  27.1±5.2 27.3±5.6 0.68 
Cause of HFrEF    0.96 
Ischaemic, n(%) 422 (61.4) 422 (61.4)  
Non-ischaemic, n(%) 266 (38.6) 266 (38.6)  
NYHA, n(%)    0.59 
I 74 (10.8) 87 (12.6)  
II 369 (53.6) 369 (53.6)  
III 233 (33.9) 220 (32.0)  
IV 3 (0.4) 5 (0.7)  
LVEF, %  29±9 29±9 0.99 
BPsys, mmHg  122±21 122±21 0.99 
Sinus rhythm, n(%)  368 (53.5) 353 (51.3) 0.42 
HR, 1/min  68±13 69±13 0.50 
NT-proBNP, pg/mL  
1,065 
(482-2,170) 
1,311 
(604-2,881) 
0.03 
Creatinine, µmol/L  102 (83-125) 99 (82-123) 0.93 
eGFR, mL/min/1.73m² 62 (47-80) 62 (47-80) 0.68 
Sodium, mmol/L 139±3 139±3 0.34 
Potassium, mmol/L  4.5±0.4 4.5±0.5 0.23 
Haemoglobin, g/dL 13.6 ± 1.6 13.7 ± 1.7 0.20 
Comorbidities, n(%)    
OPD  82 (11.9) 73 (10.6) 0.44 
R1_Table 2-4
aHT 262 (38.1) 269 (39.1) 0.70 
Hyperlipidaemia  345 (50.1) 339 (49.3) 0.75 
Smoker  109 (15.8) 101 (14.7) 0.55 
Stroke  61 (8.9) 54 (7.8) 0.50 
PVD  47 (6.8) 37 (5.4) 0.26 
Diabetes  152 (22.1) 165 (24.0) 0.41 
Treatment    
ACEI dose equivalent, %  
100  
(50-100)  
100  
(50-100)  
1.00 
Beta-blocker, n(%)  585 (85.0) 576 (83.7) 0.50 
Beta-blocker dose equivalent, %  53 (26-100) 53 (26-100) 0.62 
ARB, n(%)  25 (3.6) 33 (4.8) 0.28 
MRA, n(%)  212 (30.8) 224 (32.6) 0.22 
Loop diuretic, n(%)  558 (81.1) 540 (78.5) 0.23 
Loop diuretic dose, mg 
furosemide  
40 (40-80) 40 (20-80) 0.007 
Aspirin, n(%)  249 (36.2) 249 (36.2) 1.00 
Statin, n(%)  352 (52.6) 370 (53.8) 0.67 
Values shown are mean±SD or median (interquartile range). P-values <0.05 are written in italics. n, number; ACEI, 
angiotensin converting enzyme inhibitor; BMI, body mass index; HFrEF, heart failure with reduced ejection fraction; NYHA, 
New York Heart Association; LVEF, left ventricular ejection fraction; BPsys, systolic blood pressure; HR, heart rate; eGFR, 
estimated glomerular filtration rate calculated using the Modification of Diet in Renal Disease equation; OPD, obstructive 
pulmonary disease; aHT, arterial hypertension; PVD, peripheral vascular disease; ARB, angiotensin receptor antagonist; 
MRA, mineralocorticoid receptor antagonist. Dose equivalent represent percentage achieved of the individual drug with 
respect to the guideline recommended target dose. 
 
  
Table 3: Baseline characteristics of matched CHF patients treated with lisinopril or ramipril 
 Lisinopril 
n=622 
Ramipril 
n=622 
P-value 
Age, y  70±12 70±12 0.57 
Men, n(%)  464 (74.6) 456 (73.3) 0.61 
BMI, kg/m²  27.1±5.4 26.9±5.0 0.41 
Cause of HFrEF    0.57 
Ischaemic, n(%) 360 (57.9) 371 (59.6)  
Non-ischaemic, n(%) 262 (42.1) 251 (40.4)  
NYHA, n(%)    0.99 
I 74 (12.2) 72 (11.7)  
II 315 (51.7) 318 (51.6)  
III 210 (34.5) 215 (34.9)  
IV 10 (1.6) 11 (1.8)  
LVEF, %  30±9 30±8 0.92 
BPsys, mmHg  125±22 125±22 0.82 
Sinus rhythm, n(%)  332 (53.4) 331 (53.2) 0.96 
HR, 1/min  70±14 70±14 0.75 
NT-proBNP, pg/mL  
1,178 
(491-2,778) 
1,481 
(646-3,637) 
0.12 
Creatinine, µmol/L  102 (84-127) 102 (85-127) 0.58 
eGFR, mL/min/1.73m² 59 (46-76) 60 (46-75) 0.76 
Sodium, mmol/L 140±3 140±3 0.23 
Potassium, mmol/L  4.4±0.4 4.4±0.5 0.31 
Haemoglobin, g/dL 13.8±1.5 13.6±1.7 0.13 
Comorbidities, n(%)    
OPD  72 (11.6) 66 (10.6) 0.59 
aHT 219 (35.2) 220 (35.4) 0.95 
Hyperlipidaemia  271 (43.6) 255 (41.0) 0.36 
Smoker  100 (16.1) 82 (13.2) 0.15 
Stroke  45 (7.2) 46 (7.4) 0.92 
PVD  29 (4.7) 26 (4.2) 0.68 
Diabetes  111 (17.8) 108 (17.4) 0.82 
Treatment    
ACEI dose equivalent, %  
75  
(50-100)  
75  
(50-100)  
0.99 
Beta-blocker, n(%)  512 (82.3) 514 (82.6) 0.88 
Beta-blocker dose equivalent, %  53 (26-100) 53 (26-100) 0.19 
ARB, n(%)  14 (2.3) 12 (1.9) 0.69 
MRA, n(%)  162 (26.0) 155 (24.9) 0.13 
Loop diuretic, n(%)  502 (80.7) 495 (79.6) 0.62 
Loop diuretic dose, mg 
furosemide  
40 (30-80) 40 (40-80) 0.06 
Aspirin, n(%)  218 (35.0) 211 (33.9) 0.68 
Statin, n(%)  328 (52.7) 322 (51.8) 0.73 
Values shown are mean±SD or median (interquartile range). P-values <0.05 are written in italics. n, number; ACEI, 
angiotensin converting enzyme inhibitor; BMI, body mass index; HFrEF, heart failure with reduced ejection fraction; NYHA, 
New York Heart Association; LVEF, left ventricular ejection fraction; BPsys, systolic blood pressure; HR, heart rate; eGFR, 
estimated glomerular filtration rate calculated using the Modification of Diet in Renal Disease equation; OPD, obstructive 
pulmonary disease; aHT, arterial hypertension; PVD, peripheral vascular disease; ARB, angiotensin receptor antagonist; 
MRA, mineralocorticoid receptor antagonist. Dose equivalent represent percentage achieved of the individual drug with 
respect to the guideline recommended target dose. 
 
  
Table 4: Baseline characteristics of matched CHF patients treated with enalapril or lisinopril. 
 Enalapril 
n=538 
Lisinopril 
n=538 
P-value 
Age, y  69±12 69±12 0.71 
Men, n(%)  408 (75.8) 409 (76.0) 0.94 
BMI, kg/m²  26.9±5.1 27.1±5.0 0.63 
Cause of HFrEF    0.46 
Ischaemic, n(%) 324 (60.2) 312 (58.0)  
Non-ischaemic, n(%) 214 (39.8) 226 (42.0)  
NYHA, n(%)    0.66 
I 55 (10.3) 71 (13.5)  
II 285 (53.4) 281 (53.3)  
III 190 (35.6) 170 (32.3)  
IV 4 (0.7) 5 (0.9)  
LVEF, %  30±9 30±9 0.75 
BPsys, mmHg  124±21 125±22 0.44 
Sinus rhythm, n(%)  286 (53.2) 281 (52.2) 0.76 
HR, 1/min  69±12 68±13 0.71 
NT-proBNP, pg/mL  
1,171 
(448-2,300) 
1,099 
(435-2,468) 
0.51 
Creatinine, µmol/L  104 (85-127) 102 (85-127) 0.40 
eGFR, mL/min/1.73m² 59 (45-76) 61 (47-78) 0.42 
Sodium, mmol/L 139±4 140±3 0.89 
Potassium, mmol/L  4.5±0.4 4.5±0.4 0.65 
Haemoglobin, g/dL 13.5±1.6 13.8±1.4 0.02 
Comorbidities, n(%)    
OPD  62 (11.5) 61 (11.9) 0.85 
aHT 195 (36.2) 198 (36.8) 0.85 
Hyperlipidaemia  248 (46.1) 252 (46.8) 0.81 
Smoker  86 (16.0) 86 (16.0) 1.00 
Stroke  45 (8.4) 44 (8.2) 0.92 
PVD  28 (5.2) 26 (4.8) 0.78 
Diabetes  106 (19.7) 100 (18.6) 0.64 
Treatment    
ACEI dose equivalent, %  
100  
(50-100)  
100  
(50-100)  
0.99 
Beta-blocker, n(%)  444 (82.5) 447 (83.1) 0.81 
Beta-blocker dose equivalent, %  53 (26-100) 53 (39-100) 0.15 
ARB, n(%)  18 (3.3) 13 (2.4) 0.36 
MRA, n(%)  150 (27.9) 150 (27.9) 0.85 
Loop diuretic, n(%)  435 (80.9) 437 (81.2) 0.88 
Loop diuretic dose, mg 
furosemide  
40 (40-80) 40 (40-80) 0.33 
Aspirin, n(%)  184 (34.2) 193 (35.9) 0.57 
Statin, n(%)  281 (52.2) 288 (53.5) 0.67 
Values shown are mean±SD or median (interquartile range). P-values <0.05 are written in italics. n, number; ACEI, 
angiotensin converting enzyme inhibitor; BMI, body mass index; HFrEF, heart failure with reduced ejection fraction; NYHA, 
New York Heart Association; LVEF, left ventricular ejection fraction; BPsys, systolic blood pressure; HR, heart rate; eGFR, 
estimated glomerular filtration rate calculated using the Modification of Diet in Renal Disease equation; OPD, obstructive 
pulmonary disease; aHT, arterial hypertension; PVD, peripheral vascular disease; ARB, angiotensin receptor antagonist; 
MRA, mineralocorticoid receptor antagonist. Dose equivalent represent percentage achieved of the individual drug with 
respect to the guideline recommended target dose. 
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